Mammary Ductal Carcinoma is an indication for drug development with over 8 pipeline drugs currently active. According to GlobalData, preregistered drugs for Mammary Ductal Carcinoma have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Mammary Ductal Carcinoma compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Mammary Ductal Carcinoma overview

Ductal carcinoma is a type of breast cancer that occurs in the milk ducts and moves into nearby tissues. There are two types of ductal carcinoma, invasive ductal carcinoma (IDC) and ductal carcinoma in situ (DCIS). If the abnormal cancer cells are seen inside the milk ducts, then it is DCIS. DCIS is also known as intraductal carcinoma or non-invasive ductal carcinoma. If the cancer occurs in the lining of milk ducts and invades the breast tissue beyond duct walls, then it is IDC. IDC is also known as infiltrating ductal carcinoma or ductal adenocarcinoma.

For a complete picture of PTSR and LoA scores for drugs in Mammary Ductal Carcinoma, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.